By: Tristan Manalac
Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.
Tristan Manalac is a journalist for BioSpace, focusing on the pharmaceutical and biotech industries. With a keen interest in drug approvals, clinical trial data, and industry developments, Tristan provides insightful coverage of the latest advancements and challenges in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .